Lapatinib-Associated Toxicity and Practical Management Recommendations

  • Moy B
  • Goss P
  • 52

    Readers

    Mendeley users who have this article in their library.
  • 79

    Citations

    Citations of this article.

Abstract

Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • B. Moy

  • P. E. Goss

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free